Single-Stage Midline Unifocalization Is Associated With Excellent Outcomes in Infants of All Ages
World Journal for Pediatric and Congenital Heart Surgery · 2025
DOI: 10.1177/21501351241293708 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal for Pediatric and Congenital Heart Surgery, 2025. Verfasst von Elisabeth Martin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA, USA. Hauptthemen laut MEDLINE: Cardiac Surgical Procedures, Heart Defects, Congenital, Pulmonary Artery, Pulmonary Atresia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Objective
Tetralogy of Fallot, pulmonary atresia, and major aortopulmonary collateral arteries are a complex congenital heart defect. For years, our program has recommended early single-stage midline unifocalization at three to six months of age. However, many patients are referred beyond six months. Thus, we sought to evaluate surgical outcomes according to age at repair.
Methods
We performed a retrospective review of patients who underwent unifocalization from age 3 to 12 months. These patients had not undergone prior surgery at our institution or elsewhere and were also not protocoled into early surgery. Patients were divided in the following groups: 3.0 to 4.9 (n = 61), 5.0 to 5.9 (n = 56), 6.0 to 7.9 (n = 56), and 8.0 to 11.9 (n = 47) months. Competing risk regression analyses were performed.
Results
We included 220 patients from 2001 to 2020. Baseline characteristics were not significantly different among the four groups. Overall, single-stage complete repair with bilateral unifocalization, ventricular septal defect closure, atrial septal defect closure, and right ventricular–pulmonary artery (PA) conduit placement was achieved at the index operation in 174 (79%) patients and did not differ across age groups. Early mortality was 4% (n = 9). At one year, 91% (200/220) of the entire cohort was fully septated. Comparing with group 1, group 4 was significantly less likely to undergo any PA reinterventions [hazard ratio (HR) 0.44, 95% CI 0.21-0.92, P = .028] or surgical PA reinterventions [HR 0.12, 95% CI 0.02-0.95, P = .044] following complete repair.
Conclusions
Given the excellent outcomes across all ages, surgical timing for single-stage unifocalization should be dictated by clinical and anatomic details, with potential advantage in select clinically appropriate older infants who appear to be at a lower probability of PA reinterventions following full septation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiothoracic Surgery, Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA, USA.
- Department of Pediatrics, Lucile Packard Children's Hospital, Stanford University, Stanford, CA, USA.
- Department of Anesthesiology, Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA, USA.
ORCID-Profile: Elisabeth Martin
Zitieren
APA
Martin, E., Ma, M., Zhang, Y., Asija, R., Shek, J., Ramamoorthy, C., Hanley, F. L., & McElhinney, D. B. (2025). Single-Stage Midline Unifocalization Is Associated With Excellent Outcomes in Infants of All Ages. World Journal for Pediatric and Congenital Heart Surgery. https://doi.org/10.1177/21501351241293708
Vancouver
Martin E, Ma M, Zhang Y, Asija R, Shek J, Ramamoorthy C, et al. Single-Stage Midline Unifocalization Is Associated With Excellent Outcomes in Infants of All Ages. World Journal for Pediatric and Congenital Heart Surgery. 2025. doi:10.1177/21501351241293708
BibTeX
@article{Martin2025,
author = {Martin, Elisabeth and Ma, Michael and Zhang, Yulin and Asija, Ritu and Shek, Jennifer and Ramamoorthy, Chandra and Hanley, Frank L and McElhinney, Doff B},
title = {Single-Stage Midline Unifocalization Is Associated With Excellent Outcomes in Infants of All Ages},
journal = {World Journal for Pediatric and Congenital Heart Surgery},
year = {2025},
doi = {10.1177/21501351241293708}
}
EUVIMED